Lee Alvin, Chia Sing Joo
Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Department of Urology, Tan Tock Seng Hospital, Singapore.
Asian J Urol. 2015 Oct;2(4):187-193. doi: 10.1016/j.ajur.2015.08.003. Epub 2015 Sep 3.
Despite being the third commonest cancer in Singaporean men, there is a dearth of basic data on the detection rate of prostate cancer and post-procedure complication rates locally using systematic 12-core biopsy. Our objective is to evaluate prostate cancer detection rates using 12-core prostate biopsy based on serum prostate specific antigen (PSA) levels and digital rectal examination (DRE) findings in Singaporean men presenting to a single tertiary centre. The secondary objective is to evaluate the complication rates of transrectal prostate biopsies.
We retrospectively examined 804 men who underwent first transrectal-ultrasound (TRUS) guided 12-core prostate biopsies from January 2012 to April 2014. Prostate biopsies were performed on men presenting to a tertiary institution when their PSA levels were ≥4.0 ng/mL and/or when they had suspicious DRE findings.
Overall prostate cancer detection rate was 35.1%. Regardless of DRE findings, patients were divided into four subgroups based on their serum PSA levels: 0-3.99 ng/mL, 4.00-9.99 ng/mL, 10.00-19.99 ng/mL and ≥20.00 ng/mL and their detection rates were 9.5%, 20.9%, 38.4% and 72.3%, respectively. The detection rate of cancer based on suspicious DRE findings alone was 59.2% compared to 36.5% based on serum PSA cut-off of 4.0 ng/mL alone. The post-biopsy admission rate for sepsis was 1.5%.
In conclusion, using contemporary 12-core biopsy methods, the local prostate cancer detection rate based on serum PSA and DRE findings has increased over the past decade presumably due to multiple genetic and environmental factors. Post-biopsy sepsis remains an important complication worldwide.
尽管前列腺癌是新加坡男性中第三大常见癌症,但当地使用系统性12针活检的前列腺癌检出率及术后并发症发生率的基础数据却很匮乏。我们的目的是评估在一家单一的三级中心就诊的新加坡男性中,基于血清前列腺特异性抗原(PSA)水平和直肠指检(DRE)结果,采用12针前列腺活检的前列腺癌检出率。次要目的是评估经直肠前列腺活检的并发症发生率。
我们回顾性研究了2012年1月至2014年4月期间接受首次经直肠超声(TRUS)引导下12针前列腺活检的804名男性。当男性的PSA水平≥4.0 ng/mL和/或有可疑的DRE结果时,对在三级医疗机构就诊的男性进行前列腺活检。
总体前列腺癌检出率为35.1%。无论DRE结果如何,根据血清PSA水平将患者分为四个亚组:0 - 3.99 ng/mL、4.00 - 9.99 ng/mL、10.00 - 19.99 ng/mL和≥20.00 ng/mL,其检出率分别为9.5%、20.9%、38.4%和72.3%。仅基于可疑DRE结果的癌症检出率为59.2%,而仅基于血清PSA临界值4.0 ng/mL的检出率为36.5%。活检后败血症的入院率为1.5%。
总之,使用当代的12针活检方法,过去十年中基于血清PSA和DRE结果的当地前列腺癌检出率有所提高,这可能是多种遗传和环境因素所致。活检后败血症仍是全球范围内的一个重要并发症。